Sabine Schmatloch
0000-0002-0131-7515
Publication & Citation Trends
Publications
0 total
Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer
Cited by 0
Semantic Scholar
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatin in patients with HER2-negative BC and HRD -long-term survival of the GeparOLA study.
Cited by 3
Semantic Scholar
Abstract RF2-02: Axillary surgery after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Treatment algorithms and prognostic impact of residual micrometastases in five neoadjuvant studies
Cited by 0
Semantic Scholar
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification OA
Cited by 1
Semantic Scholar
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs
Cited by 16
Semantic Scholar
Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, HER2‐negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial
Cited by 0
Semantic Scholar
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk OA
Cited by 3
Semantic Scholar
Abstract PO5-22-12: Development and Validation of a Genomic Test to Predict Tumor Response of the Axillary Nodes after Neoadjuvant Chemotherapy (NAC) in Patients with HER2-negative Breast Cancer: Results of the AGO-35 trial
Cited by 0
Semantic Scholar
Research Topics
Cancer Treatment and Pharmacology
(72)
Breast Cancer Treatment Studies
(58)
HER2/EGFR in Cancer Research
(57)
Advanced Breast Cancer Therapies
(41)
Caveolin-1 and cellular processes
(35)
Affiliations
University of Kassel
Universität Hamburg
Johannes Gutenberg University Mainz
Heidelberg University
University of Würzburg